1. Methods
Quantification of phenacetin and paracetamol
For sample preparation, an aliquot of 80 μL plasma sample was pipetted into a 1.5 mL Eppendorf tube, followed by addition of 10 μL internal standard working solution (1 μg/mL pseudoephedrine hydrochloride, IS-1), 10 μL methanol, and 50 μL saturated NaHCO3. Analytes were extracted with 800 μL ethyl acetate by vortexing for 3 min, and then centrifuged at 8000 rpm for 10 min at 4 ℃. A total of 750 μL aliquot of the organic layer was evaporated to dryness under a gentle stream of nitrogen at 37 ℃, and the resulting residue was reconstituted in 80 μL methanol- The calibration standard ranges used for phenacetin and paracetamol were 5-8000 μg/L and 10-8000 μg/L, respectively.
Untargeted metabolomics analysis
Serum and liver sample pretreatment, GC-MS and LC-MS analysis, data preprocessing, and metabolite identification were all based on our previous studies [1] [2] [3] .
Sample pretreatment
For frozen liver samples, liver homogenates were prepared first. The same part of the left lobe of the liver from each rat was taken for tissue sample preparation. Ten volumes of pre-cold methanol were added to approximately 100 mg liver samples, followed by homogenization three times (5.5 m/s for 30 s) with 60 s intervals between each step. After two centrifugations (14,000 rpm, 4 ℃, 10 min), the supernatant was removed for metabolomic analysis. Serum samples were thawed at room temperature. For GC-MS analysis, 100 μL methanol was added to a 10 μL aliquot of serum or liver homogenate, and the mixture was thoroughly vortex-mixed for 15 min. After two centrifugations (14,000 rpm, 4 ℃, 10 min), 80 μL supernatant was transferred to a brown glass vial, and then oximated with 25 μL MOX (10 mg/mL in pyridine) at 1200 rpm for 90 min at 37 ℃. After vacuum drying (Labconco CentriVap, Kansas, MO, United States), the residue was silylated with 120 μL MSTFA:ethyl acetate (1:4, v/v) by incubating at 37 ℃ for 120 min, and then the supernatant was separated for GC-MS analysis.
For LC-MS analysis, 20 μL serum or 50 μL liver homogenate was thoroughly mixed with 140 μL or 100 μL acetonitrile, respectively. After a second centrifugation (4 ℃, 14000 rpm, 10 min), the supernatant was separated for LC-MS analysis.
GC-MS analysis
GC-MS analysis was performed on GCMS-QP2010 Ultra (Shimadzu Inc., Kyoto, Japan) equipped with a Rtx-5MS capillary column (30 m × 0.25 mm ID, 0.25 μm, Restek, USA). Helium was employed as the carrier gas at a flow rate of 1mL/min. The oven temperature was initially set at 70 ℃ for 3 min, followed by an increase to 320 ℃ (10 ℃/min), and maintained at 320 ℃ for 2 min. The temperature of the injector, transfer line, and ion source were set at 250, 250, and 200 ℃, respectively. The mass spectrometer was operated in electron impact mode with the energy of 70 eV. Data acquisition was performed in full san mode with a 45-600 mass to charge ratio (m/z) range.
A 1 μL sample was injected, with the split ratio of 50:1. GCMS solution version 2.7 (Shimadzu Inc., Kyoto, Japan) was used for spectra acquisition and data processing.
LC-MS analysis
LC-MS analysis was performed on an ultra-fast liquid chromatography (UFLC) system coupled with ion trap/time-of-flight hybrid mass spectrometry (IT/TOF-MS, Shimadzu Inc., Kyoto, Japan). Chromatographic separation was achieved by a Phenomenex Kinetex C18 column (100 × 2.1 mm, 2.6 μm, Phenomenex, United States). The column temperature was set at 40 ℃. The gradient elution with 0.4 mL/min flow rate (phase A: 0.1% formic acid, phase B: acetonitrile) was carried out from 95% A to 5% A within 20 min and maintained at 5% A for 3 min. For mass analysis, ESI was set in both positive and negative ion mode with a 100-1000 m/z san range. The TOF analyzer detector voltage was 1.8 kV, and the interface voltage was set at 4.5 kV and -3.5 kV for positive and negative mode, respectively. The curved desorption line and heat block temperature were both set at 200 ℃. Nitrogen was used as the nebulizing gas, with a flow rate of 1.5 L/min. A 5 μL sample was injected for analysis. LCMS solution version 3.0 (Shimadzu Inc., Kyoto, Japan) was used for spectra acquisition and data processing.
Data preprocessing
Each chromatogram obtained from GC-MS and LC-MS analysis was processed for peak deconvolution and alignment using Profiling Solution version 1.1 (Shimadzu, Kyoto, Japan), followed by background-peak-filtering, 80% rule, limitation of QCs, missing data imputation, and normalization. The details of each step were as follows [3]:
(1) Background-peak filtering: each chromatogram was checked against the solvent blanks (inserted randomly in the analytical batch) to exclude possible sources of contamination, such as instrumental contamination or reagent impurities.
(2) 80% rule: retained the variables which were detectable in more than 80% samples in at least one group to minimize the effect of the missing values.
(3) QC sample limitation: removed the variables with RSD values higher than 30% in QC samples.
(4) Missing data imputation and normalization: replaced the missing values with a half of the minimum value found in the dataset. After the total area normalization for each sample, a resulting matrix was obtained and then prepared for further differential features screening and metabolite identification.
Metabolites identification
For GC-MS analysis, metabolites were preliminarily identified by a comparison of mass spectra and intensities with those available in National Institute of Standards and Technology (NIST 11) library. To minimize false discovery rates, only those peaks with similarity more than 75% were assigned for compound names and considered reliable. Some of the metabolites were further confirmed by standard compounds available in our lab.
For LC-MS analysis, the metabolites formulae were initially predicted by comparison of theoretical and observed m/z values and isotopic patterns using Formula Predictor in LCMS Solution software. Then the m/z values, formulae and the MS/MS fragmentations information were compared with those provided by existing literature and online databases, such as HMDB For sample preparation, a total of 160 μL acetonitrile and 10 μL internal standard working solution (50 μg/mL 13 C1-leucine, IS-2) were added to 40 μL serum or liver homogenate and vortexmixed for 5 min. After centrifugation (4 ℃, 14,000 rpm, 10 min), an aliquot of 125 μL supernatant was transferred into another 1.5 mL Eppendorf tube and evaporated by vacuum drying at 37 ℃.
Subsequently, the residue was dissolved in 50 μL 1% formic acid. Finally, the reconstituted extract was centrifuged (4 ℃, 14,000 rpm, 10 min) and the supernatant was separated for LC-MS/MS analysis. Supplementary Table S1 .
The calibration standard ranges used for biomarkers in serum and liver were 0.25-50 μg/mL and 2.5-500 μg/g, respectively.
in lipid metabolism in survival and non-survival rats treated with lipopolysaccharide. Supplementary Table   S2 . The mRNA levels were normalized by β-actin expression and expressed as the fold change relative to control. Data are presented as mean ± SD, and n = 8 for each group. Unpaired Student's t-test. *** p < 0.001. C: control group; BNF: β-naphthoflavone treatment group; F: fold change.
3. Tables   Table S1 . CYP1A2 mRNA level was calculated using the 2 -∆Ct method and normalized by β-actin expression.
Data are presented as mean ± SD, and n = 8 for each group. Ct: cycle threshold; △Ct = Ct of CYP1a2 -Ct of β-actin; C: control group; BNF: β-naphthoflavone treatment group. normalization data in untargeted metabolomics. ↓decreasing change trend after β-naphthoflavone administration. ↑increasing change trend after β-naphthoflavone administration. The value of the metabolic ratio reflected the activity of CYP1A2, and a higher value represented a higher activity.
CYP1A2 mRNA expression was calculated using the 2 -∆Ct method. Ct: cycle threshold; △Ct = Ct of CYP1a2 -Ct of β-actin. Data are presented as mean ± SD; n = 8 for each group. C: control group; BNF: β-naphthoflavone treatment group. Data are presented as mean ± SD; n = 8 for each group. C: control group; BNF: β-naphthoflavone treatment group.
